Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
National Resilience LLC is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and the distinct art units. This distribution shows a diversified prosecution strategy, where each pending matter is being reviewed by a different examiner in a different administrative unit. The company's current workload is spread across these various points of contact within the patent office.
The busiest examiner for the company is STEVENS, MARK V, who is responsible for 1 busiest examiner pending office action. This examiner handles a portion of the total pending office actions, meaning the workload involves multiple distinct examiners. This lack of concentration means that the company's prosecution outcomes are not tied to a single individual's review. Practitioners must navigate the specific requirements of the distinct art units, requiring a strategy that accounts for the different administrative practices in each unit to ensure consistency across the various filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555446 | PEPTIDES, NANOVESICLES, AND USES THEREOF FOR DRUG DELIVERY | STEVENS, MARK V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555446 | PEPTIDES, NANOVESICLES, AND USES THEREOF FOR DRUG DELIVERY | STEVENS, MARK V | — |
| 18056931 | Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555446 | PEPTIDES, NANOVESICLES, AND USES THEREOF FOR DRUG DELIVERY | STEVENS, MARK V | 1613 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18056931 | Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof | ZARA, JANE J | 1637 | Other | Non-Final OA | — | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial